Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 5
2011 2
2012 7
2013 16
2014 19
2015 36
2016 31
2017 35
2018 34
2019 49
2020 37
2021 49
2022 46
2023 41
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

358 results

Results by year

Filters applied: . Clear all
Page 1
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
BACKGROUND: Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with substantial morbidity and mortality in advanced disease stages. We compared the efficacy of mogamulizumab, a novel monoclonal antibody directed against C-C chemokine receptor 4, with v …
BACKGROUND: Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with substantial morbidity and mortality in advanced dis …
Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H, Kamachi K, Kimura S. Ureshino H, et al. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):326-331. doi: 10.1016/j.clml.2019.03.004. Epub 2019 Mar 23. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30981611 Review.
Mogamulizumab, a defucosylated humanized monoclonal antibody against the C-C chemokine receptor 4 (CCR4), has been approved for the treatment of relapsed adult T-cell leukemia/lymphoma (ATL). Compared with conventional chemotherapy, mogamulizumab monotherapy …
Mogamulizumab, a defucosylated humanized monoclonal antibody against the C-C chemokine receptor 4 (CCR4), has been approved for the t …
Mogamulizumab for the treatment of T-cell lymphoma.
Makita S, Tobinai K. Makita S, et al. Expert Opin Biol Ther. 2017 Sep;17(9):1145-1153. doi: 10.1080/14712598.2017.1347634. Epub 2017 Jul 3. Expert Opin Biol Ther. 2017. PMID: 28649848 Review.
T-cell lymphoma is a relatively rare hematologic malignancy that accounts for 10-20% of non-Hodgkin lymphomas. ...Among various subtypes of T-cell lymphomas, adult T-cell leukemia-lymphoma (ATL) has the worst prognosis. ...
T-cell lymphoma is a relatively rare hematologic malignancy that accounts for 10-20% of non-Hodgkin lymphomas. ...Among variou …
Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.
Ollila TA, Sahin I, Olszewski AJ. Ollila TA, et al. Onco Targets Ther. 2019 Feb 7;12:1085-1094. doi: 10.2147/OTT.S165615. eCollection 2019. Onco Targets Ther. 2019. PMID: 30799938 Free PMC article. Review.
Cutaneous T-cell lymphoma (CTCL) poses unique treatment challenges, given its range of presentations and numerous systemic therapy options. ...Further research may establish incremental efficacy of combining mogamulizumab with cytotoxic or immunomodulatory agents in …
Cutaneous T-cell lymphoma (CTCL) poses unique treatment challenges, given its range of presentations and numerous systemic therapy op …
Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Tawa M, Kopp E, McCann S, Cantrell W. Tawa M, et al. Clin J Oncol Nurs. 2019 Aug 1;23(4):E73-E80. doi: 10.1188/19.CJON.E73-E80. Clin J Oncol Nurs. 2019. PMID: 31322628 Review.
BACKGROUND: Cutaneous T-cell lymphoma (CTCL), including subtypes mycosis fungoides (MF) and Sezary syndrome (SS), represents a rare group of non-Hodgkin lymphomas. ...METHODS: Case studies are used to describe the role of mogamulizumab in CTCL and to review p …
BACKGROUND: Cutaneous T-cell lymphoma (CTCL), including subtypes mycosis fungoides (MF) and Sezary syndrome (SS), represents a rare g …
Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
de Lartigue J. de Lartigue J. Drugs Today (Barc). 2012 Oct;48(10):655-60. doi: 10.1358/dot.2012.48.10.1885878. Drugs Today (Barc). 2012. PMID: 23110261 Review.
T-cell neoplasms, such as adult T-cell leukemia/lymphoma (ATL) and peripheral T-cell lymphoma, are particularly aggressive and, despite novel combination chemotherapy regimens, still have extremely poor prognoses. ...Mogamulizumab is a humanized antibody, wit …
T-cell neoplasms, such as adult T-cell leukemia/lymphoma (ATL) and peripheral T-cell lymphoma, are particularly aggressive and …
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K. Izutsu K, et al. Blood. 2023 Mar 9;141(10):1159-1168. doi: 10.1182/blood.2022016862. Blood. 2023. PMID: 36150143 Free PMC article. Clinical Trial.
Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor prognosis and few treatment options for patients with relapsed, recurrent, or refractory disease. ...Patients pretreated with mogamulizumab had an ORR of 45.8% (4 complete an …
Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor prognosis and few treatment options for p …
Mogamulizumab.
[No authors listed] [No authors listed] 2019 Apr 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 Apr 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643268 Free Books & Documents. Review.
Mogamulizumab is a humanized monoclonal antibody to the T cell CC chemokine receptor 4 which is used to treat peripheral and cutaneous T-cell lymphomas. Mogamulizumab is associated with a low rate of serum enzyme elevations during treatment and has been linke …
Mogamulizumab is a humanized monoclonal antibody to the T cell CC chemokine receptor 4 which is used to treat peripheral and cutaneou …
A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.
Afifi S, Mohamed S, Zhao J, Foss F. Afifi S, et al. Expert Opin Drug Saf. 2019 Sep;18(9):769-776. doi: 10.1080/14740338.2019.1643837. Epub 2019 Jul 17. Expert Opin Drug Saf. 2019. PMID: 31303060 Review.
Introduction: Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas of skin-homing T-cells that initially or mainly manifest cutaneously. ...Finally, the authors evaluate the safety of mogamulizumab in comparison to other agents available in CTCL. …
Introduction: Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas of skin-homing T-cells that initially or mainly …
Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential.
Duvic M, Evans M, Wang C. Duvic M, et al. Ther Adv Hematol. 2016 Jun;7(3):171-4. doi: 10.1177/2040620716636541. Epub 2016 Mar 17. Ther Adv Hematol. 2016. PMID: 27247757 Free PMC article. Review.
Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4). It has shown promising therapeutic potential in phase I and II clinical trials and is currently being investigated for efficacy in treatin …
Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4) …
358 results